搜索
ss
ss
关于普米斯
About Us
t7

PM1003

Biotheus' 4-1BB agonist is a humanized VHH that targets a unique membrane-proximal epitope on 4-1BB situated on the CRD4 domain to maintain agonist activity but in turn reduce toxicity risk. Activation of 4-1BB can improve immune effector function and memory. By pairing with an anti-PD-L1 binder, PM1003 can both inhibit PD-L1 function and activate 4-1BB in PD-L1-enriched tumours. Fc function has been depleted to reduce effector function towards PD-L1+ and 4-1BB+ cells and minimize FcR-mediated crosslinking. In preclinical studies, single-agent activity has been observed, and PM1003 may be used for treating multiple solid tumour types.
t7
Product description
Parameters

Biotheus' 4-1BB agonist is a humanized VHH that targets a unique membrane-proximal epitope on 4-1BB situated on the CRD4 domain to maintain agonist activity but in turn reduce toxicity risk. Activation of 4-1BB can improve immune effector function and memory. By pairing with an anti-PD-L1 binder, PM1003 can both inhibit PD-L1 function and activate 4-1BB in PD-L1-enriched tumours. Fc function has been depleted to reduce effector function towards PD-L1+ and 4-1BB+ cells and minimize FcR-mediated crosslinking. In preclinical studies, single-agent activity has been observed, and PM1003 may be used for treating multiple solid tumour types.

Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
Previous
There is currently no content to display
Please add data record on website background.
There is currently no content to display
Please add data record on website background.

Copyright © 2022 Biotheus Inc. All Rights Reserved  粤ICP备2021122492号